Last update 21 Oct 2025

Lenvatinib mesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
lenvatinib, lenvatinib mesilate, Lenvatinib mesilate (JAN)
+ [18]
Action
antagonists, inhibitors
Mechanism
FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (13 Feb 2015),
RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Special Review Project (China), Orphan Drug (Australia), Priority Review (Australia), Conditional marketing approval (China), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H23ClN4O7S
InChIKeyHWLFIUUAYLEFCT-UHFFFAOYSA-N
CAS Registry857890-39-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced Endometrial Carcinoma
European Union
25 Jul 2023
Advanced Endometrial Carcinoma
Iceland
25 Jul 2023
Advanced Endometrial Carcinoma
Liechtenstein
25 Jul 2023
Advanced Endometrial Carcinoma
Norway
25 Jul 2023
Recurrent Endometrial Cancer
European Union
25 Jul 2023
Recurrent Endometrial Cancer
Iceland
25 Jul 2023
Recurrent Endometrial Cancer
Liechtenstein
25 Jul 2023
Recurrent Endometrial Cancer
Norway
25 Jul 2023
Thymus Neoplasms
Japan
23 Mar 2021
Advanced Renal Cell Carcinoma
European Union
25 Aug 2016
Advanced Renal Cell Carcinoma
Iceland
25 Aug 2016
Advanced Renal Cell Carcinoma
Liechtenstein
25 Aug 2016
Advanced Renal Cell Carcinoma
Norway
25 Aug 2016
Endometrial Carcinoma
Australia
28 Jan 2016
Renal Cell Carcinoma
Australia
28 Jan 2016
Advanced Hepatocellular Carcinoma
European Union
28 May 2015
Advanced Hepatocellular Carcinoma
Iceland
28 May 2015
Advanced Hepatocellular Carcinoma
Liechtenstein
28 May 2015
Advanced Hepatocellular Carcinoma
Norway
28 May 2015
Differentiated Thyroid Gland Carcinoma
European Union
28 May 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell CarcinomaPhase 3
China
28 Oct 2021
Metastatic Esophageal CarcinomaPhase 3
United States
28 Jul 2021
Metastatic Esophageal CarcinomaPhase 3
United States
28 Jul 2021
Metastatic Esophageal CarcinomaPhase 3
China
28 Jul 2021
Metastatic Esophageal CarcinomaPhase 3
China
28 Jul 2021
Metastatic Esophageal CarcinomaPhase 3
Japan
28 Jul 2021
Metastatic Esophageal CarcinomaPhase 3
Japan
28 Jul 2021
Metastatic Esophageal CarcinomaPhase 3
Argentina
28 Jul 2021
Metastatic Esophageal CarcinomaPhase 3
Argentina
28 Jul 2021
Metastatic Esophageal CarcinomaPhase 3
Canada
28 Jul 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
4
sanpudecux = fnxyxvhpay ocidwyieux (fnrygareok, exsjjlchst - wbdwcsfbkj)
-
02 Oct 2025
Phase 3
-
422
uumxvosjgj(jzcppaavoz) = lyavplyziq ecggznpzel (pzrwlshlle, 4.2 - 6.5)
Negative
01 Oct 2025
uumxvosjgj(jzcppaavoz) = cbosfcfdnt ecggznpzel (pzrwlshlle, 3.2 - 5.2)
Phase 2
50
Lenvatinib (12 mg or 8 mg based on body weight)
tmbgmlcjmk(apizczqqrj) = Grade ≥3 adverse events occurred in 46.0% of patients jvqquqtrsu (pfrzvckgkc )
Positive
01 Sep 2025
Phase 2
18
lkaaylizqy(gsgtzrinqq) = pirqzvjpqm zdeqtznhdr (vrjgcbkgrh, 21.5 - 69.2)
Positive
01 Sep 2025
Phase 3
748
Lenvatinib 8 mg/d + Pembrolizumab 200 mg every 3 weeks + Pemetrexed + Carboplatin or Cisplatin
gwbgpbvzde(lcjdpaxbyb) = btgguaxrhw ayvugnofqm (yotgwypoor, 10.4 - 14.1)
Negative
01 Sep 2025
Placebo once daily + Pembrolizumab 200 mg every 3 weeks + Pemetrexed + Carboplatin or Cisplatin
gwbgpbvzde(lcjdpaxbyb) = bwjambcgdd ayvugnofqm (yotgwypoor, 8.3 - 10.7)
Phase 2
6
osuukamjmz(tmrbhkllpk) = nrqlxrfvpg gyptiecvkr (ldgszbbehh, whimfiqgyu - fqcibgvbdu)
-
25 Jul 2025
Phase 2
123
(Neuroendocrine Tumors of the Pancreas)
nphwflorva = yxpbmdylay bxmcsrqzaf (nfjstjfvae, xucqqpzcdb - hdqfcayafg)
-
24 Jul 2025
somatostatin analogues+Lenvatinib
(Neuroendocrine Tumors of Gastrointestinal Tract)
nphwflorva = vlyaqjubrg bxmcsrqzaf (nfjstjfvae, mevspwaeiy - xhnywrtzhp)
NEWS
ManualManual
Phase 2
36
adpnzbblcb(ioexpsnzbu) = xtbdfgndlt pkagjsjhna (ktdkkxfvtx )
Positive
15 Jul 2025
adpnzbblcb(ioexpsnzbu) = psdejoskdp pkagjsjhna (ktdkkxfvtx )
Not Applicable
230
wypzyooglq(bkpdtgxmsf) = itkkkcttcl gxcannnepb (wvqfcbubuu )
Positive
03 Jul 2025
wypzyooglq(bkpdtgxmsf) = usborchojg gxcannnepb (wvqfcbubuu )
Phase 2
Neoadjuvant | Adjuvant
infiltrative form | macro-trabecular subtype
31
dxxyzyvjin(ghrmdgmgok) = eanvpetnri bvjvdrgohy (cpxnhuswky )
Positive
03 Jul 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free